Slowing of Brain Atrophy and Reductions in New Multiple Sclrosis Lesions Sustained at Three Years in Patients Treated with Genzyme's Lemtrada TM
- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada
did not receive a third course of treatment in the first year of the extension -
PARIS, April 30, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program.
for Sanofi: Slowing of Brain Atrophy and Reductions in New MS Lesions Sustained at Three Years in Patients Treated with Genzyme's Lemtrada investment picks